Nucleus RadioPharma, Inc. announced that it will issue 10,547,047 series A preferred shares at issue price of $5.8879 per share for the gross proceeds $62,099,958.0313 in funding on September 15, 2023. The shares are convertible, and non-redeemable. The shares will be convertible in common shares at a price of $5.8879 per share.